Improving quality of life through the routine use of the patient concerns inventory for head and neck cancer patients: baseline results in a cluster preference randomised controlled trial by Rogers, Simon N et al.
European Archives of Oto-Rhino-Laryngology
 
Improving quality of life through the routine use of the patient concerns inventory for





Full Title: Improving quality of life through the routine use of the patient concerns inventory for
head and neck cancer patients: baseline results in a cluster preference randomised
controlled trial
Article Type: Head &amp; Neck (Original Article)
Keywords: Head and neck cancer;  intervention;  prompt list;  health related quality of life;
randomised trial;  Patient Concerns Inventory;  cluster preference





Corresponding Author's Institution: University Hospital Aintree
Corresponding Author's Secondary
Institution:
First Author: Simon N Rogers, FRCS MD
First Author Secondary Information:




























Order of Authors Secondary Information:
Funding Information: Research for Patient Benefit Programme
(PB-PG-0215-36047)
Professor Simon N Rogers
Abstract: Purpose: The main aim of this paper is to present baseline demographic and clinical
characteristics and HRQOL in the two groups of the Patient Concerns Inventory (PCI)
trial. The baseline PCI data will also be described. 
Methods: This is a pragmatic cluster preference randomised control trial with 15
consultant clusters from two sites either ‘using' (n=8) or ‘not using’ (n=7) the PCI at
clinic for all of their trial patients.  The PCI is a 56-item prompt list that helps patients
raise concerns that otherwise might be missed. Eligibility was head and neck cancer
patients treated with curative intent (all sites, stage of disease, treatments). 
Results: From 511 patients first identified as eligible when screening for the multi-
disciplinary tumour board meetings, 288 attended a first routine outpatient baseline
study clinic after completion of their treatment, median (IQR) of 103 (71-162) days. At
baseline, the two trial groups were similar in demographic and clinical characteristics
as well as in HRQOL measures apart from differences in tumour location, tumour
staging and mode of treatment. These exceptions were cluster (consultant) related with
Maxillofacial and ENT consultants seeing different types of cases. Consultation times
were similar, with PCI group times taking about one minute longer on average (95% CL
for the difference between means was from -0.7 to +2.2 minutes).
Conclusion: Using the PCI in routine post-treatment head and neck cancer clinics does
not elongate consultations.   Recruitment has finished but 12-month follow-up is still
ongoing.
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Thank you for the feedback in response our submission. The comments and suggestions are 
very much appreciated.   
We have addressed the reviewers comments as indicated below. The changes to the 
manuscript have been highlighted in red font. 
 
Reviewer #1: Overall, well written and well thought over description of study setup and 
introduction to the expected results. 
Thank you for the comment 
 
Some minor issues: 
1.Abstract: This WAS a trial....would say this IS a trial ... still running 
Thank you for pointing this out. The abstract has been amended. 
Change: ‘This is a pragmatic……’ 
 
2. p 3 line 3: I don't see very well how carry-over effects would act here...maybe best to 
explain to the reader 
In order to help clarify this we have made two changes:  
a sentence in the material and methods section  
Change: ‘….randomisation was ruled out because of the likely sensitization of consultants to 
using the PCI. Such sensitization could lead to certain strategies being carried over to when 
control group patients were being seen, and consequently a possible dilution of any 
intervention effect. It is also….’ 
A sentence in the discussion 
Change: ‘….The choice of a cluster design is a strength of the study because randomisation 
of consultants avoided contamination and possible dilution of results by consultants being 
sensitized with the PCI process. An additional robustness to the trial is the relatively……’ 
 
 
3. P 9 §1: "Consultation times were similar between the two groups indicating that the 
use of the PCI did not appear to have impacted on the timetabling of clinic sessions": I 
would like to see you expand on the way that the PCI-raised issues facilitate 
communication and adequate referral to paramedics and in this way maybe the same 
time span is used more efficiently 
 
Two sentences in the discussion and one further reference has been added 
Change:  ‘…..not appear to have impacted on the timetabling of clinic sessions. There is 
evidence around the benefit of questionnaire prompt lists [7]and how its use re-directs the 
focus of the consultation time onto those most pertinent issues for each patient [27]. 
Furthermore, from the issues raised on the PCI, this allows the HN team to apportion the 
necessary type and level of healthcare and supportive interventions, hence a more efficient 





Authors' response to reviewers' comments
4. At table 1: these median consultation times are very short for first visits... maybe 
good to specify what this consultation times entail. 
 
Four sentences in the discussion and one further reference has been added 
Change: ‘able to incorporate items identified seamlessly into their consultations. Previous 
taped consultations have revealed that the time spent on physical examination in the 
consultation room, such as palpation of the neck, mouth examination and nasendoscopy takes 
just a few minutes [28]. As nasendoscopy takes longer this might account for consultation 
time difference between ENT and MFU. In addition, it is possible to have relatively short 
consultations as these are set in the context of ongoing intervention from a range of 
professionals such as Clinical Nurse Specialist, Speech and Language Therapist, Dietitian, 
and Physiotherapists. Patients use the opportunity outside of the consultation, either by 
phone, email, or face to face, to access their support if this is not explicitly triggered during 
the clinic visit.’ 
 
 
furthermore QOL at baseline does seem different between intervention and control 
groups - not really commented upon 
 
This point has triggered two changes to the manuscript. 
 
One sentence has been added to methods 
Change: ‘……clustering as well as for baseline variables including baseline value of the 
QOL measure. Secondary outcomes…’ 
 
One sentence has been added to discussion 
Change: ‘awaited the strongest predictors are yet to be identified. We will also adjust for 
baseline value of the QOL outcome so as to adjust for any imbalances between PCI and 
control groups.’ 
 
We hope that is sufficient to clarify the issue as whatever slight imbalances there might be at 
baseline regarding the main QOL measures we will in the final analyses be analysing for 
effect size using regression methods after adjusting for case-mix variables as independent 
predictors including baseline value of the QOL measure as well as for consultant clustering 
 
 
Reviewer #2: Excellent work. Very thorough cientific proces which frequently lacks 
amongst head and neck cancer publications.  
 
Thank you for the comment 
 
My only suggestion would be to add the researchers point of view as to how this 
improves patients experience and justify why this doesn´t seem to have an impact on the 
ultimate QOL of our patients. 
 
Thank you for this comment. It is very hard for us to address this at the moment. We are 
conducting some interviews during the course of the trial but these are not yet available. Of 
course, the outcome of the study in terms of QOL is still awaited. 
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Purpose: The main aim of this paper is to present baseline demographic and clinical 
characteristics and HRQOL in the two groups of the Patient Concerns Inventory (PCI) trial. 
The baseline PCI data will also be described.  
Methods: This is a pragmatic cluster preference randomised control trial with 15 consultant 
clusters from two sites either ‘using' (n=8) or ‘not using’ (n=7) the PCI at clinic for all of 
their trial patients.  The PCI is a 56-item prompt list that helps patients raise concerns that 
otherwise might be missed. Eligibility was head and neck cancer patients treated with 
curative intent (all sites, stage of disease, treatments).  
Results: From 511 patients first identified as eligible when screening for the multi-
disciplinary tumour board meetings, 288 attended a first routine outpatient baseline study 
clinic after completion of their treatment, median (IQR) of 103 (71-162) days. At baseline, 
the two trial groups were similar in demographic and clinical characteristics as well as in 
HRQOL measures apart from differences in tumour location, tumour staging and mode of 
treatment. These exceptions were cluster (consultant) related with Maxillofacial and ENT 
consultants seeing different types of cases. Consultation times were similar, with PCI group 
times taking about one minute longer on average (95% CL for the difference between means 
was from -0.7 to +2.2 minutes). 
Conclusion: Using the PCI in routine post-treatment head and neck cancer clinics does not 
elongate consultations.   Recruitment has finished but 12-month follow-up is still ongoing.  
 
 
Keywords; head and neck cancer; intervention; prompt list; health related quality of life; 
randomised trial; Patient Concerns Inventory; cluster preference 
 
Introduction 
Following head and neck cancer (HNC) patients can experience substantial physical, 
emotional and social dysfunction as post-treatment consequences effects many aspects with 
detrimental impact on health-related quality of life (HRQOL) [1,2].  These in turn can lead to 
Blinded Manuscript Click here to view linked References
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a significant burden of unmet supportive care needs [3].  There is evidence that given the 
opportunity patients value the chance to discuss their concerns [4]. There are various tools 
available to assist the clinician in the identification of potential unmet needs in the HNC 
setting, of which the Patient Concerns Inventory (PCI) is one. In a systematic review 
Shunmugasundaram et al recommended the PCI, particularly when considering the 
importance of content validity over quantitative psychometric properties [5]. The PCI is a 
condition-specific item prompt list [6] and is based on the literature around the use of 
questionnaire prompt lists in consultations [7].  It consists of 56 items, which patients select 
from before their appointment, to help guide the outpatient consultation, which covers a 
range of symptoms and potential problems individuals may confront after treatment. The PCI 
helps to focus the consultation, to aid doctor-patient communication, and to signpost patients 
to other professionals for advice and support [8]. It is a tool that can be integrated into routine 
clinical practice [9]. 
 
Although pilot work has confirmed that most patients wish to continue to use the PCI in their 
consultations [10], and that its inclusion alters the items discussed with clinicians and 
potentially improves HRQOL [11, 12], there is a lack of evidence from a randomised trial of 
patient benefit, which has prompted this novel trial [13]. By conducting a pragmatic, cluster-
based, multi-centre randomised controlled trial (C-RCT) involving several consultants, it will 
be possible to evaluate with rigour, whether the repeated inclusion of the PCI in routine post-
treatment consultations does make a significant and clinically meaningful difference in 
patient-reported HRQOL and distress. 
The main aim of this paper is to present baseline demographic and clinical characteristics and 
HRQOL in the two groups of the Patient Concerns Inventory (PCI) trial. Also, to describe the 
baseline PCI data. The baseline data provides the opportunity to describe HRQOL and patient 
concerns relatively early on in the post-treatment trajectory. Having a greater understanding 
of early post-treatment issues and challenges could help shape interventions at this critical 
time of adaptation to the cancer diagnosis and the consequences of treatment.  
 
Material and methods 
 
The study methods have been described previously [13]. Briefly, this is a pragmatic cluster-
controlled trial, with consultants (clusters) randomised to ‘using’ or ‘not using’ an 
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intervention incorporating the PCI prompt list at all their trial clinics. Individual patient 
randomisation was ruled out because of the likely sensitization of consultants to using the 
PCI. Such sensitization could lead to certain strategies being carried over to when control 
group patients were being seen, and consequently a possible dilution of any intervention 
effect. It is also a consultant preference trial, by which those with preferences were given 
their preferred group and those with no preference were randomised. This was to limit the 
chance of PCI-sceptic consultants dominating the PCI group and PCI-enthusiastic consultants 
the non-PCI group. The allocation process was overseen by the trial medical statistician, 
before any patient recruitment occurred. Two centres participated. In Leeds, three of six 
consultants preferred to be in the PCI group, while the three others had no preference and 
were placed in the control group.  In Liverpool, three of eight consultants preferred to be 
controls and the other five had no preference: one was randomised to the control group and 
the other four were placed in the PCI intervention group. One newly appointed consultant at 
Liverpool joined the trial soon after it started and was randomised to the PCI group.   
 
Sample size calculations required 312 patients from 10 or more consultants to show (with 
80% power, 5% level of significance) a halving in the percentage with less than good overall 
quality of life at the final follow-up clinic, i.e. at one-year on from the (baseline) first routine 
outpatient clinic after completion of treatment. With an expected 25% loss through attrition 
and non-consent, 416 was the required number to be identified at Multidisciplinary Team 
(MDT) Meetings.   Eligible patients were given an information sheet about the trial and if 
willing they were asked to sign a consent form when they next attended hospital.   Patients 
consented to their clinical data being used and to completing research questionnaires before 
each post-treatment consultation, some of which could be used in their consultation. Neither 
consultants nor patients were blind to the randomisation; this was a pragmatic trial. Eligible 
patients were treated curatively for primary HNC, and all sites, stage of disease and 
treatments were included.  Patients with a second primary tumour were also accepted from 
January 2018. Patients treated palliatively and patients with a recurrence were excluded, as 
were patients with a history of cognitive impairment, psychoses or dementia.  Eligible 
patients who later started palliative care discontinued their participation. Unit Clinical Trials 
Nurses recruited patients and dedicated funded Unit researchers collected baseline clinical 
and demographic data using a baseline clinic questionnaire based on that of the Head and 
Neck 5000 project [14], or by extraction from baseline clinical records. Index of Multiple 
Deprivation (IMD 2019) scores were derived from patient postcodes using publicly available 
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data [15] and these provide a relative measure of deprivation at a small area level across 
England. Trial Quality Assurance included initial training and immediate post consultation 
feedback from PCI patients about how much use had been made of the PCI prompt list.  
 
Pre-consultation questionnaires including the PCI prompt list were completed electronically 
(desktop, tablet, iPAD) apart from at one Liverpool hospital (non-PCI consultant) which used 
paper because of technical issues. All PCI intervention group patients were then given a sheet 
of paper summarising their data which they took into their consultations (Figure 1). This 
sheet listed (a) all the PCI items they had selected for discussion, (b) any University of 
Washington (UWQOL) questionnaire domains in which a significant problem or dysfunction 
was indicated, (c) their overall UWQOL response and (d) their Distress Thermometer score.  
This summary sheet was the visible difference between the trial arms as far as the contact 
between consultant and patient was concerned. Control patients completed exactly the same 
pre-clinic information as intervention patients apart from the PCI prompt list, but crucially 
both they and their consultant did not see any summary sheet.  
 
Measures 
The UW-QOL v4 questionnaire consists of 12 single item domains, these having between 3 
and 5 response options scaled evenly from 0 (worst) to 100 (best) according to response 
hierarchy [16]. UW-QOL domains are presented within two subscales, physical function and 
social-emotional function [17].  The physical function score is the mean of the appearance, 
swallowing, chewing, speech, taste and saliva domain scores, while the social-emotional 
function score is the mean of the pain, activity, recreation, shoulder, mood and anxiety 
domain scores. Criteria derived from earlier work can be used to indicate the domains in 
which patients have a significant problem or dysfunction [18]. Question domains for intimacy 
and fears of recurrence were also developed using a similar system of possible responses as 
the UWQOL v4 [19,20]. There is also a single item overall QOL question on the UWQOL v4 
for which patients are asked to consider not only physical and mental health, but also other 
factors, such as family, friends, spirituality or personal leisure activities important to their 
enjoyment of life.  The trial primary outcome measure is the percentage of patients with less 
than good overall QOL at the final one-year clinic. As inference will target the individual 
patient level, the final analyses will include adjustment for consultant clustering as well as for 
baseline variables including baseline value of the QOL measure. Secondary outcomes include 
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the mean social-emotional subscale score of the UWQOL-v4 and a Distress Thermometer 
(DT) score of 4 or more [21]. These will be reported once the trial has finished. HRQOL data 
also included the EQ-5D-5L [22].  
Statistical analysis 
For cluster randomised trials the risk of chance imbalance is greater than for individual 
patient randomisation because of the relatively small number of clusters involved. It is 
therefore prudent to present relevant summary baseline information for both clusters 
(consultants) and patients. Fishers Exact (for categorical variables) and the Mann-Whitney 




Recruitment process and participation rate 
Patients recruited to the trial and having baseline data were first discussed at MDT meetings 
between January 2017 and December 2018, with baseline trial clinics between April 2017 
and October 2019. MDT meetings identified 511 potentially eligible patients (Figure 2), with 
288 attending baseline clinics a median (IQR) of 194 (125-249) days after diagnosis and 103 
(71-162) days after the end of treatment. The 223 patients not starting the trial included 111 
who could not possibly have started it because of what materialised in the time lag between 
MDT and the trial baseline clinic to make them ineligible;  these comprised 48 lost through 
death,  tumour recurrence or palliation, 21 lost because it was more convenient for some 
patients to travel to a non-trial site, 22 because of delays in trying to agree an electronic 
system at one hospital and 20 for clinical reasons (in another trial, mental health, not HNC, 
2nd Primary). The other 112 patients lost to the trial comprised 71 due to consent being 
refused, 5 who withdrew consent, 9 by missed opportunity to recruit within a busy outpatient 
clinic environment, 6 when there was no translator available, 4 with exclusions outside the 
trial protocol (clinical opinion, patient age) and 17 lost to follow-up/unknown status.  All 15 
eligible consultants from the two locations took part in the trial, with a median (range) of 16 
(5-48) patients attending baseline clinics. 
 
Randomisation baseline comparisons  
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At the cluster (consultant) level there was similarity between trial groups in the number of 
patients per consultant, median consultation times, mean patient ages, and experience (Table 
1). There was also similarity in regard to the primary outcome variable as measured at 
baseline, i.e. the percentage with less than good overall quality of life, as well as for key 
secondary measures, namely the mean social-emotional subscale score of the UWQOL and 
the percentage of patients reporting a distress thermometer score of four or more.  However, 
there were differences between trial groups in the type of patient (tumour location and 
staging) seen by consultants and in treatments administered. PCI group consultants had fewer 
patients with oral cavity tumours, more with advanced tumour staging and more receiving 
radiotherapy and chemotherapy. These differences in consultant case-mix transferred through 
to patient level (Table 2), though less markedly reflecting the way the variation in patients per 
consultant has played out in the aggregation of data. Apart from these differences the two 
trial groups were similar in demographic and clinical characteristics. Of particular note is that 
consultation times were very similar, with PCI group times taking about one minute longer 
on average (95% confidence interval for the difference between means was from 0.7 of a 
minute less to 2.2 minutes longer). There was also similarity in regard to the primary 
outcome variable as measured at baseline, as well as for the key secondary measures, and 
also across a wide range of baseline QOL measures (Table 3).   
 
Baseline study population characteristics  
Median (IQR) age at baseline clinic of the 288 patients was 62 (55-69) years and 69% (198) 
were male. For 47% (134) the tumour was located in the oral cavity, 32% (91) oropharynx, 
14% (41) larynx and 8% (22) in other places. All but 6 tumours were squamous cell (SCC).  
Clinical staging was early (0-2) for 43% (124) and advanced (3-4) for 57% (164). Treatment 
for 40% (116) comprised surgery alone while 6% (16) received radiotherapy without surgery, 
15% (42) radiotherapy and chemotherapy without surgery, 32% (92) surgery with adjuvant 
radiotherapy and 8% (22) surgery with adjuvant radiotherapy and chemotherapy. Free-flap 
transfer occurred for 29% (67/230) of operations, and specifically for 46% (60/130) of 
tumours in the oral cavity, 8% (5/61) oropharynx, 4% (1/23) larynx and 6% (1/16) other 
locations. WHO comorbidities were at level 1 for 23% (67), level 2 for 13% (36), levels 3-4 
for 2% (6). ACE 27 comorbidities were mild for 33% (95), moderate for 17% (48) and severe 
for 3% (8). Most patients had smoked with 13% (37/280) currently smoking at the time of the 
baseline questionnaire, 58% (163/280) being former smokers and 29% (80/280) having never 
smoked.  Two-thirds (69%, 194/280) continued to drink alcohol, 26% (73/280) no longer did 
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so and 5% (13/280) had never drank alcohol. One quarter (23%, 65/286), lived alone in a 
house or flat, 31% (88/280) were still working in paid employment, and 40% (107/265) were 
in receipt of financial benefits.   Some 38% (110/288) of patients lived in an area that is 
ranked nationally (England) within the most deprived 20% of areas, according to overall 
deprivation scores (IMD 2019).  
 
Overall QOL was outstanding for 6% (18), very good for 30% (87), good for 33% (94), fair 
for 22% (63), poor for 6% (17) and very poor for 3% (9); i.e.  31% (89) had overall QOL that 
was less than good and 69% (199) had overall QOL that was good or better. Also, 45% (129) 
stated Distress Thermometer values of ≥4 and the median (IQR) UWQOL emotional subscale 
score was 75 (59-88). Dysfunction in regard to UWQOL items were notably higher in regard 
to salivation (34%, 99), pain (29%, 83), fears of recurrence (26%, 75) and taste (20%, 57).  
 
The mean number of items selected by 140 PCI patients for discussion in their consultation 
was 6.60, median (IQR) 5 (2-9), range 0 to 28 with 15 or more items selected by 9% (13) 
(Table 4). Nearly half (48%) of patients selected ‘dry mouth’ to discuss and other items 
selected by more than 20% were ‘fear of cancer coming back’ (34%), ‘dental health/teeth’ 
(34%), ‘chewing/eating’ (33%),  ‘salivation’ (33%), ‘fatigue/tiredness’ (29%), ‘swallowing’ 
(28%), ‘taste’ 27%, ‘sore mouth’ (24%), ‘mucus’ (24%), ‘shoulder’ (22%), ‘pain in the head 
and neck’ (21%) and ‘cancer treatment’ (20%), (Table 4, Figure 3).  Almost all the immediate 
post-consultation feedback was positive in that the PCI had been used ‘a great deal’ or 
‘somewhat’ in the consultation.  The PCI results were broadly similar for the two sites 
involved in the trial.  
 
Discussion  
The main focus of this paper is to assess the baseline balance in this trial.  Ivers et al 
comment that many cluster randomised trials (C-RCTs) have too few clusters to reasonably 
expect cluster level balance [23]. They cite a review of C-RCTs with a median of 21 clusters 
per trial with 25% having fewer than 12 clusters. Our trial recruited 15 consultant clusters and 
we have presented data at both cluster and patient levels.  The two trial groups were broadly 
similar at the patient level in demographic and clinical characteristics and over a wide range 
of QOL measures, apart from differences in regard to tumour location, tumour staging and 
the mode of treatment. These exceptions are cluster (consultant) related with Maxillofacial 
and ENT consultants seeing different types of cases. Baseline imbalances are unimportant if 
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the variable concerned is unrelated to outcome, while strong predictors of outcome are 
important even if statistically non-significant [24]. It is important to identify strong baseline 
predictors and to adjust for these in the final analyses [25]. Our trial protocol named age, 
gender, treatment, overall clinical stage, and tumour site as case-mix variables that will be 
adjusted for. As the outcome data is awaited the strongest predictors are yet to be identified. 
We will also adjust for baseline value of the QOL outcome so as to adjust for any imbalances 
between PCI and control groups. 
 
A one year unfunded extension to the trial was necessary for various reasons. Firstly, the 
MDT identified potential patients in a wide catch all net so as not to miss eligible patients but 
in so doing this process flagged patients who on closer scrutiny could never have been 
included had the consenting process taken place at the first post-treatment routine clinical 
outpatient review. This applied to 50% of those lost to the trial between MDT and trial 
baseline clinic. Secondly there were delays in setting up the IT capacity (iPAD) at a spoke 
unit and after several months trying to resolve this issue it was decided to allow paper 
completion because this involved only one non-PCI consultant. Vigilance of the clinical trials 
team at this site enabled robust data completion. IT difficulties do raise a wider issue around 
future rollout of the PCI approach in HNC consultations across the NHS and currently a 
cloud-based platform is being explored. A third reason for extending the trial period was a 
longer time lag to baseline clinic than originally expected. The first baseline surgeon 
consultant review was at around six months following diagnosis, with a trial follow-up period 
of another year. Even with this trial extension to allow more patients to be recruited, the final 
outcomes will be analysed on fewer numbers than planned, probably on around two-thirds of 
the intended number. In hindsight an extra trial hospital would have been useful to the trial 
but we have to be pragmatic and in the final analyses accept that “size and power are 
irrelevant once the experiment has actually been carried out. At this point the trial is analysed 
using confidence intervals to show the plausible values for the treatment effects” [26]. 
 
The choice of a cluster design is a strength of the study because randomisation of consultants 
avoided contamination and possible dilution of results by consultants being sensitized with 
the PCI process. An additional robustness to the trial is the relatively small proportion of 
refusals and withdrawals, though this was anticipated given the very high participation levels 
for using the PCI in routine non-trial settings [4,9,10]. The number missed for logistical 
reasons was also small. Good patient and consultant recruitment allows confidence in respect 
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of representativeness and acceptance of the PCI approach into clinical practice. Another 
strength of the trial was the electronic data capture which has virtually eliminated missing 
data in the outpatient clinic setting apart from the trial baseline questionnaires which patients 
could complete as they wished and from post-consultation feedback information of PCI 
patients.   
 
The baseline assessment reflects survivors at a median of six months after diagnosis and three 
months after the end of treatment and their clinical characteristics are typical of a HNC 
patient population. HRQOL data highlights the dysfunction relating to salivation/dry mouth 
both in the UWQOL and as the most commonly raised issue on the PCI. There was also 
notable dysfunction in regard to pain and in fearing their cancer would return, and these 
issues were also commonly raised on the PCI. Whereas just over two-thirds of patients 
regarded their overall QOL as being good or better, distress levels were relatively high with 
nearly half having Distress Thermometer scores of four or more.  
 
Consultation times were similar between the two groups indicating that the use of the PCI did 
not appear to have impacted on the timetabling of clinic sessions. There is evidence around 
the benefit of questionnaire prompt lists [7]and how its use re-directs the focus of the 
consultation time onto those most pertinent issues for each patient [27]. Furthermore, from 
the issues raised on the PCI, this allows the HN team to apportion the necessary type and 
level of healthcare and supportive interventions, hence a more efficient use of time and 
personalized approach to routine follow-up care [27]. The PCI consultations were only about 
one minute longer than non-PCI consultations and this should have no bearing on delivery 
across the NHS. There is good indication from the immediate post consultation 
questionnaires that the PCI was being used ‘a great deal’ at baseline and this will also be 
tracked over later clinics. One of the main criticisms that has been raised about the PCI is the 
possibility that by allowing patients to raise a lot of issues this will extend the consultation 
time unduly. The median number of PCI items selected was 5, with an inter-quartile range of 
2 to 9, which implies that the vast majority of patients do have issues they want to talk about 
and sometimes they have a lot of issues with 1 in 10 patients having selected 15 or more 
items at these trial baseline clinics. This raises the issue of prioritisation within consultation 
and anecdotal feedback from PCI consultant training sessions would suggest that they are 
able to incorporate items identified seamlessly into their consultations. Previous taped 
consultations have revealed that the time spent on physical examination in the consultation 
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room, such as palpation of the neck, mouth examination and nasendoscopy takes just a few 
minutes [28]. As nasendoscopy takes longer this might account for consultation time 
difference between ENT and MFU. In addition, it is possible to have relatively short 
consultations as these are set in the context of ongoing intervention from a range of 
professionals such as Clinical Nurse Specialist, Speech and Language Therapist, Dietitian, 
and Physiotherapists. Patients use the opportunity outside of the consultation, either by 
phone, email, or face to face, to access their support if this is not explicitly triggered during 
the clinic visit. 
 
As the trial is set within the context of NHS practice and involved 15 consultants across two 
centres, the findings should have generalisability. Recruiting clusters is often more difficult 
than recruiting individuals [23], however in this trial all eligible consultants agreed to 
participate.  The choice of a cluster design is a strength of the study because randomisation of 
consultants avoided contamination and possible dilution of results by consultants being 
sensitized with the PCI process. Patients were allocated to individual consultants through the 
cancer tracking referral process and there was no selection bias based on knowing which 
consultants were using PCI and which were not. This has been a source of contamination in 
other trials [29]. Anecdotally, there was very little discussion observed between trial patients 
by the trial staff in the waiting room prior to consultations, which minimises any possible 
dilution of any effects of the intervention.    
 
Conclusion 
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Figure 1: Patient Flow Diagram 
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• Missed opportunity (7) 
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Patients with baseline clinic  data  (n=148) 
 1 
Table 1. Baseline comparisons at the cluster (consultant) level  
  PCI 
 group 
Control group 
Consultant level:    
No of consultants (patients)  8 (140) 7 (148) 
No of patients in trial 




Year started as a consultant  




Specialty ENT or MFU   5 ENT, 3 MFU 2 ENT, 5 MFU 




Range: 7, 8,10,11,11,12,12 




















    
% of patients with tumour location Oral cavity 
Median:  15 
Range: 0,0,4,7,22,80,89,100 
Median:  77 
Range: 0,2,77,77,82,85,100 
 Oropharynx 
Median:  37 
Range: 0,6,7,33,40,46,56,56 
Median:  15 
Range: 0,8,9,15,18,60,73 
 Larynx 
Median:  22 
Range: 0,0,7,11,32,38,40,44 
Median:  0 
Range: 0,0,0,0,0,19,40 
 Other 
Median:  7 
Range: 0,0,6,6,7,13,18,33 
Median:  6 
Range: 0,0,0,6,6,8,15 










UWQOL Overall Quality of life %Less than good 
Median:  34 
Range: 22,22,25,32,35,38,40,40 
Median:  27 
Range: 0,23,24,27,33,38,42 
UWQOL social-emotional subscale Median 
Median: 78  
Range: 65,70,76,78,78,83,83,85 
Median:  78 
Range: 63,67,69,78,78,83,85 
Distress thermometer (DT) % >=4 
Median:  56 
Range: 30,32,33,56,56,60,63,67 
Median:  54 
Range: 29,31,31,54,55,60,67 
 
Note: the results underlined are those of the three consultants with fewer than 10 study patients. These results are liable 





Table 2. Baseline case-mix comparisons at the patient level  





Hospital Aintree 59% (82) 65% (96) 
0.28 
 Leeds 41% (58) 35% (52) 
Days from diagnosis to baseline clinic Median (IQR) 189 (120-255) 195 (125-244) 0.68 
Days from end of treatment to baseline clinic Median (IQR) 108 (70-165) 102 (75-160) 0.90 
Duration of consultation (minutes) 
Mean, Median (IQR) 
11.9, 11 (8-15), 
n=137 
11.1, 10 (7-13), 
n=147 
0.09 
Gender Female 35% (49) 28% (41) 0.20 
Age at baseline Median (IQR) 63 (57-69) 60 (53-68) 0.12 
Ethnicity A1 (White British) 99% (138) 95% (141) 0.17 
Tumour site: Oral cavity 39% (55) 53% (79) 
0.002 
 Oropharynx 30% (42) 33% (49) 
 Larynx 21% (30) 7% (11) 
 Other 9% (13) 6% (9) 
Clinical T stage 3-4 21% (30) 24% (36) 0.58 
Clinical N stage Positive 54% (75) 44% (65) 0.13 
     
Overall stage 0/I 26% (36) 32% (48) 
0.47 
 II 14% (20) 14% (20) 
 III 20% (28) 14% (21) 
 IV 40% (56) 40% (59) 
Primary treatment Surgery only 38% (53) 43% (63) 
0.02 
 RT only 9% (13) 2% (3) 
 RT&CT only 18% (25) 11% (17) 
 Surgery& RT  27% (38) 36% (54) 
 Surgery &RT&CT 8% (11) 7% (11) 
Free-flap transfer YES 25% (25/102) 33% (42/128) 0.19 
WHO comorbidity  0 63% (88) 61% (91) 
0.28  1 20% (28) 26% (39) 
 2-4 17% (24) 12% (18) 
ACE27 comorbidity None 51% (71) 45% (66) 
0.52 
 Mild 29% (41) 36% (54) 
 Moderate 18% (25) 16% (23) 
 Severe 2% (3) 3% (5) 
Living situation Alone in house/flat 21% (29) 25% (36/146) 0.48 
Working Yes 36% (48/134) 27% (40/146) 0.16 
Financial benefits Yes 39% (49/127) 42% (58/138) 0.62 
Smoking habit Current 12% (16/135) 14% (21/145) 
0.77  Former 60% (81/135) 57% (82/145) 
 Never 28% (38/135) 29% (42/145) 
Alcohol habit Current 74% (100/135) 65% (94/145) 
0.25  Former 22% (30/135) 30% (43/145) 
 Never 4% (5/135) 6% (8/145) 
IMD 2019 quintile 1=least deprived 11% (16) 12% (18) 
0.83 
 2 21% (29) 18% (26) 
 3 16% (22) 18% (27) 
 4 12% (17) 16% (23) 
 5=most deprived 40% (56) 36% (54) 
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Table 3. Baseline clinic QOL comparisons at the patient level 
    
  PCI group Control group 
  N=140 N=148 
Main outcome measures:    
UWQOL Overall Quality of life Less than good 32% (45) 30% (44) 
UWQOL social-emotional subscale Mean, Median (IQR) 75, 78 (64-87) 70, 72 (55-88) 
Distress thermometer (DT) Score ≥4 47% (66) 43% (63) 
    
Other measures:    
UWQOL Overall Quality of life Outstanding 8% (11) 5% (7) 
 Very good 26% (36) 34% (51) 
 Good 34% (48) 31% (46) 
 Fair 24% (34) 20% (29) 
 Poor 4% (5) 8% (12) 
 Very Poor 4% (6) 2% (3) 
UWQOL physical function subscale Mean, Median (IQR) 69, 69 (57-86) 67, 68 (53-86) 
    
UWQOL items 
 
   
Social-emotional subscale    
 Pain Best possible response  38% (53) 37% (55) 
 Dysfunction 28% (39) 30% (44) 
 Activity Best possible response  33% (46) 27% (40) 
 Dysfunction 10% (14) 14% (20) 
 Recreation Best possible response  44% (61) 32% (48) 
 Dysfunction 6% (8) 10% (15) 
 Shoulder Best possible response  61% (85) 51% (75) 
 Dysfunction 10% (14) 15% (22) 
 Mood Best possible response  34% (48) 33% (49) 
 Dysfunction 12% (17) 19% (28) 
 Anxiety Best possible response  34% (47) 38% (56) 
 Dysfunction 17% (24) 17% (25) 
Physical function subscale    
 Appearance Best possible response  31% (43) 22% (32) 
 Dysfunction 8% (11) 11% (17) 
 Swallowing Best possible response  36% (50) 36% (54) 
 Dysfunction 12% (17) 17% (25) 
 Chewing Best possible response  41% (57) 41% (60) 
 Dysfunction 14% (19) 13% (19) 
 Speech Best possible response  46% (64) 40% (59) 
 Dysfunction 7% (10) 9% (13) 
 Taste Best possible response  29% (41) 33% (49) 
 Dysfunction 19% (27) 20% (30) 
 Saliva Best possible response  29% (41) 26% (39) 
 Dysfunction 37% (52) 32% (47) 
Other items:    
 Intimacy Best possible response  79% (110) 69% (102) 
 Dysfunction 4% (6) 6% (9) 
 Fear of recurrence Best possible response  14% (19) 16% (24) 
Dysfunction 25% (35) 27% (40) 
EQ-5D    
Mobility Moderate/severe/unable 18% (25) 27% (40) 
Self-care Moderate/severe/unable 11% (16) 11% (16) 
Usual activities Moderate/severe/unable 21% (29) 28% (42) 
Pain Moderate/severe/extreme 31% (44) 30% (44) 
Anxiety/depression Moderate/severe/extreme 11% (15) 22% (33) 
EQ-5D-5L TTO crosswalk values Mean, Median (IQR) 0.76, 0.77 (0.68-0.88) 0.70, 0.74 (0.58-0.88) 





Table 4. Patient PCI data at the post treatment baseline clinic 
  Aintree Leeds Combined 
  N=82 N=58 N=140 
     
No of PCI selected: overall Mean, Median (IQR) 6.91, 5 (2-10) 6.16, 5 (3-8) 6.60, 5 (2-9) 
PCI items selected by domain:     
No of PCI selected: Physical function P=0.93 Mean, Median (IQR) 5.28, 4 (2-8) 4.76, 5 (2-7) 5.06, 4 (2-7) 
No of PCI selected: cancer treatment  P=0.66 Mean, Median (IQR) 0.35, 0 (0-1) 0.31, 0 (0-1) 0.34, 0 (0-1) 
No of PCI selected: social  P=0.10 Mean, Median (IQR) 0.39, 0 (0-1) 0.16, 0 (0-0) 0.29, 0 (0-0) 
No of PCI selected: psychological P=0.87 Mean, Median (IQR) 0.89, 1 (0-1) 0.93, 1 (0-1) 0.91, 1 (0-1) 
PCI items selected by at least 20% of patients Dry mouth 48% (39) 50% (29) 49% (68) 
 Fear of cancer coming back 34% (28) 34% (20) 34% (48) 
 Dental health/Teeth 30% (25) 40% (23) 34% (48) 
 Chewing/eating 34% (28) 31% (18) 33% (46) 
 Salivation 33% (27) 33% (19) 33% (46) 
 Fatigue/tiredness 27% (22) 31% (18) 29% (40) 
 Swallowing 32% (26) 22% (13) 28% (39) 
 Taste 28% (23) 26% (15) 27% (38) 
 Sore mouth  30% (25) 14% (8) 24% (33) 
 Mucus 21% (17) 28% (16) 24% (33) 
 Shoulder 22% (18) 22% (13) 22% (31) 
 Pain in the head and neck 18% (15) 26% (15) 21% (30) 
 Cancer treatment 20% (16) 21% (12) 20% (28) 
No. of Health professionals selected  Mean, Median (IQR) 1.13, 1 (0-2) 0.48, 0 (0-1) 0.86, 0 (0-1) 
 
Post consultation feedback on the PCI: 
    
Did the doctor make reference to the PCI 
prompt list during the consultation? 
Not at all - - - 
A little - 3 3 
 Somewhat 1 12 13 
 A great deal 80 37 117 
 unknown 1 6 7 
 
 
